Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Summary
To assess the multiple-dose pharmacokinetics (PK), safety and tolerability of AVP-786 (deuterated \[d6\] dextromethorphan hydrobromide \[DM\]/quinidine sulfate \[Q\]) in healthy volunteers.
Official title: A Phase 1, Single-center, Randomized, Open-label Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide/Quinidine Sulfate) in Healthy Volunteers
Key Details
Gender
MALE
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2013-09-01
Completion Date
2013-11-01
Last Updated
2026-04-28
Healthy Volunteers
Yes
Conditions
Interventions
AVP-786
AVP-923
Locations (1)
CMAX
Adelaide, South Australia, Australia